Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12122373 | 0.92 | GNRHR (0.80) | GNRHRKCNH2 | |
| SCHEMBL779750 | 0.91 | GNRHR (0.79) | GNRHRKCNH2 | |
| SCHEMBL778208 | 0.90 | GNRHR (0.78) | GNRHRKCNH2 | |
| SCHEMBL4885456 | 0.90 | GNRHR (0.86) | GNRHRKCNH2 | |
| Sufugolix SCHEMBL209021 | 0.87 | GNRHR (1.00) | GNRHR | |
| Sufugolix SCHEMBL4251869 | 0.86 | GNRHR (0.99) | GNRHR | |
| SCHEMBL778213 | 0.86 | GNRHR (0.72) | GNRHRKCNH2 | |
| SCHEMBL777399 | 0.86 | GNRHR (0.72) | GNRHRKCNH2 | |
| SCHEMBL777398 | 0.86 | GNRHR (0.72) | GNRHRKCNH2 | |
| SCHEMBL6642419 | 0.86 | GNRHR (1.00) | GNRHRKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080108623-A1 | N-(4-(1-(2,6-difluorobenzyl)-5(((2-methoxyethyl)(methyl)amino)methyl)-2,4-dioxo-3-(2-pyridinyl)-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N'-methoxyurea; gonadotropin releasing hormone (GnRH) antagonist; sex hormone dependent disease, antitumor agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108623-A1 | N-(4-(1-(2,6-difluorobenzyl)-5(((2-methoxyethyl)(methyl)amino)methyl)-2,4-dioxo-3-(2-pyridinyl)-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N'-methoxyurea; gonadotropin releasing hormone (GnRH) antagonist; sex hormone dependent disease, antitumor agent | GNRHR, KISS1R, FSHR | GNRHR 1/4885KCNH2 588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.